SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (9783)12/17/2003 1:36:57 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 52153
 
deleted



To: Sam Citron who wrote (9783)12/17/2003 1:58:50 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
I shall screen all biotech prospects for MBAs from top-tier business schools among top managerial ranks

Like Enron's Jeffrey Skilling? <g>

Believe me, it's not the MBA's you need to worry about at most biotechs.

This Flumist deal was probably driven by Wyeth, not by MEDI.

Peter



To: Sam Citron who wrote (9783)12/17/2003 4:59:05 PM
From: A.J. Mullen  Respond to of 52153
 
Apart from the need to move the product, it seems to me the price agreed with the government wasn't bad. $20 a dose wholesale might be as good as they get when selling retail at $65 - $25 rebate.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News